Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.27 is 16% above its 4-year average of -0.32, around the middle of its 4-year range (-0.39–-0.21).
4.28% below its 12-month average of -0.26.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.08.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.27
EARNINGS PER SHARE (EPS) AVG TTM
-0.26
EARNINGS PER SHARE (EPS) AVG 3Y
-0.31
EARNINGS PER SHARE (EPS) AVG 5Y
-0.32
EARNINGS PER SHARE (EPS) AVG 10Y
-0.67
EARNINGS PER SHARE (EPS) AVG 15Y
-1.59
EARNINGS PER SHARE (EPS) AVG 20Y
-2.04
CURRENT VS TTM AVG
-4.28%
CURRENT VS 3Y AVG
+12.18%
CURRENT VS 5Y AVG
+15.97%
CURRENT VS 10Y AVG
+59.89%
CURRENT VS 15Y AVG
+82.97%
CURRENT VS 20Y AVG
+86.75%
Oncolytics Biotech Inc.
Market Cap
$59.91M
Earnings Per Share (EPS)
-0.27
TTM Avg
-0.26
3Y Avg
-0.31
5Y Avg
-0.32
Market Cap
$60.05M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.64
3Y Avg
-4.21
5Y Avg
-9.38
Market Cap
$60.49M
Earnings Per Share (EPS)
-1.64
TTM Avg
-9.73
3Y Avg
-25.86
5Y Avg
-294.77
Market Cap
$60.11M
Earnings Per Share (EPS)
N/A
TTM Avg
-19.12
3Y Avg
-29.60
5Y Avg
-38.42
Market Cap
$58.99M
Earnings Per Share (EPS)
-2.39
TTM Avg
-2.92
3Y Avg
-5.17
5Y Avg
-5.77
Market Cap
$61.12M
Earnings Per Share (EPS)
-2.02
TTM Avg
-7.29
3Y Avg
-26.82
5Y Avg
-38.33
Market Cap
$58.24M
Earnings Per Share (EPS)
-13.20
TTM Avg
-15.24
3Y Avg
-17.58
5Y Avg
-15.68
Market Cap
$57.42M
Earnings Per Share (EPS)
N/A
TTM Avg
-3.23
3Y Avg
-2.68
5Y Avg
-2.37
Market Cap
$56.78M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.18
3Y Avg
-0.24
5Y Avg
-0.27
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oncolytics Biotech Inc. (ONCY) | $59.91M | -0.27 | -0.26 | -0.31 | -0.32 |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.05M | N/A | -0.64 | -4.21 | -9.38 |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.49M | -1.64 | -9.73 | -25.86 | -294.77 |
| Adicet Bio, Inc. (ACET)vs › | $60.11M | N/A | -19.12 | -29.60 | -38.42 |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.99M | -2.39 | -2.92 | -5.17 | -5.77 |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.12M | -2.02 | -7.29 | -26.82 | -38.33 |
| Fractyl Health, Inc. (GUTS)vs › | $58.24M | -13.20 | -15.24 | -17.58 | -15.68 |
| Boundless Bio, Inc. (BOLD)vs › | $57.42M | N/A | -3.23 | -2.68 | -2.37 |
| OKYO Pharma Limited (OKYO)vs › | $56.78M | N/A | -0.18 | -0.24 | -0.27 |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.16M | -1.49 | -2.95 | -2.90 | -2.58 |
Trailing EPS (TTM)
$-0.27
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2024-12-31 | -0.21 |
| 2023-12-31 | -0.31 |
| 2022-12-31 | -0.32 |
| 2021-12-31 | -0.39 |
| 2020-12-31 | -0.38 |
| 2018-12-31 | -0.78 |
| 2017-12-31 | -0.89 |
| 2016-12-31 | -0.89 |
| 2015-12-31 | -0.84 |
| 2014-12-31 | -1.73 |
| 2013-12-31 | -2.52 |
| 2012-12-31 | -4.57 |
| 2011-12-31 | -3.81 |
| 2010-12-31 | -3.04 |
| 2009-12-31 | -3.10 |
| 2008-12-31 | -3.29 |
| 2007-12-31 | -3.68 |
| 2006-12-31 | -3.21 |
| 2005-12-31 | -3.19 |
| 2004-12-31 | -3.59 |
| 2003-12-31 | -2.68 |
| 2002-12-31 | -1.74 |
| 2001-12-31 | -1.99 |
| 2000-12-31 | -1.39 |
| 1999-12-31 | -0.01 |
